Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 14, 2018 - Issue 12
Submit an article Journal homepage
581
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Current clostridium difficile treatments: Lessons that need to be learned from the clinical trials

E. C. TampakiDepartment of Propaedeutic Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece;National Organization for the Provision of Healthcare Services, Department of Planning and Monitoring of Medicines Dispensing, Medicines Division, GreeceCorrespondence[email protected]
,
A. TampakisDepartment of Propaedeutic Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece;Department of General and Visceral Surgery, University Hospital of Basel, Switzerland
,
A. PosabellaDepartment of Visceral Surgery, St. Clara Hospital, Basel, Switzerland
,
E. PatsourisDepartment of Pathology, School of Medicine, National and Kapodistrian University of Athens, Greece
,
K. KontzoglouDepartment of Propaedeutic Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece
&
G. KouraklisDepartment of Propaedeutic Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece
Pages 2874-2875 | Received 28 May 2018, Accepted 18 Jun 2018, Published online: 27 Aug 2018

References

  • Eliakim-Raz N, Bishara J. Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota. Hum Vaccin Immunother. 2018:1–4. [ Epub ahead of print]. doi:10.1080/21645515.2018.1472184.
  • Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, Satokari R. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):155. doi:10.1186/s12916-016-0698-z.
  • Committee for Medicinal Products for Human Use (CHMP). International non-proprietary name: fidaxomicin: Assessment report. European Med Agency. September 22, 2011. Pages: 83. EMA/857570/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002087/WC500119707.pdf.
  • Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305–17. doi:10.1056/NEJMoa1602615.
  • BLA 761046: Bezlotoxumab Injection Antimicrobial Drugs Advisory Committee (AMDAC). Antimicrobial Drugs Advisory Committee Meeting Briefing Document: Bezlotoxumab. US Food and Drug Administration. June 9, 2016. Pages:109
  • Committee for Medicinal Products for Human Use (CHMP). International non-proprietary name: bezlotoxumab: Assessment report. European Medicines Agency. November 22, 2016. Pages: 110. EMA/853812/2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/004136/WC500222643.pdf.
  • Dubberke ER, Mullane KM, Gerding DN, Lee CH, Louie TJ, Guthertz H, Jones C. Clearance of vancomycin-resistant enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent Clostridium difficile infection. Open Forum Infect Dis. 2016;3(3):ofw133. doi:10.1093/ofid/ofw133.
  • Lagier JC, Cadoret F, Raoult D. Critical microbiological view of SER-109. J Infect Dis. 2017;215(1):161–2. Epub 2016 Oct 20. doi:10.1093/infdis/jiw489.
  • Bézay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–92. Epub 2016 Apr 11. doi:10.1016/j.vaccine.2016.03.098.
  • Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313(17):1719–27. doi:10.1001/jama.2015.3725.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.